Consistent with the aforementioned, LSD1 inhibition also sensitizes SCLC cells to MHC-I–restricted T cell cytolysis and results in an augmented antitumor response in combination with PD-L1 blockade therapy as mentioned earlier (122). This evidence concerns the gene KDM1A and small cell lung carcinoma.